Endocr Connect. 2025 Jan 1:EC-24-0522. doi: 10.1530/EC-24-0522. Online ahead of print.
ABSTRACT
BACKGROUND: The aim is to develop age-specific anti-Müllerian hormone screening criteria for polycystic ovary syndrome to facilitate the early detection and diagnosis of the condition, and to subsequently evaluate the screening criteria.
METHODS: A retrospective analysis was performed on patient data from Hangzhou Women’s Hospital between July 2021 and August 2024. The use of restricted cubic spline analysis helped identify age-related inflection points, which were crucial for segmenting the patient population. Statistical analysis was conducted using SPSS software, and the receiver operating characteristic curve was employed to determine the area under the curve, optimal anti-Müllerian hormone screening thresholds, sensitivity, specificity, Youden index, correct diagnosis rate, positive likelihood ratio, and negative likelihood ratio. The established age-related anti-Müllerian hormone screening criteria for polycystic ovary syndrome were then validated using a separate validation group. The consistency of the polycystic ovary syndrome age-related anti-Müllerian hormone screening test with the 2003 Rotterdam polycystic ovary syndrome diagnostic criteria was assessed using the Kappa statistic.
RESULTS: The derived age-specific anti-Müllerian hormone screening thresholds for polycystic ovary syndrome were as follows: ≥5.65 ng/ml (20-27-year-old), ≥5.06 ng/ml (28-30-year-old), and ≥4.19 ng/ml (31-39-year-old).
CONCLUSION: The age-stratified anti-Müllerian hormone screening criteria demonstrated high sensitivity, specificity, and accuracy in identifying polycystic ovary syndrome, indicating a strong predictive value. However, the development of more robust and universally applicable diagnostic criteria for polycystic ovary syndrome will require additional multicenter, prospective clinical trials for further validation.
PMID:39854723 | DOI:10.1530/EC-24-0522
